The thing people say is that the FDA banned hydroquinone. The thing that actually happened is stranger and more useful to understand, because the difference explains why you can still buy it, why the packaging changed, and why the version in your bathroom cabinet may be the least regulated product you own.
The CARES Act — the 2020 pandemic relief legislation — contained a provision overhauling how over-the-counter drugs are approved. As a consequence, effective 23 September 2020, all over-the-counter skin-lightening drug products were deemed new drugs requiring FDA approval. Not withdrawn for cause. Reclassified. Manufacturers were required to pull unapproved over-the-counter products by that date, and one prescription product — Tri-Luma, a triple combination indicated for short-term treatment of moderate to severe melasma — remains the only FDA-approved hydroquinone-containing drug product in the country.
No safety review triggered this. No new evidence arrived. A procedural change in an unrelated bill swept an entire product category into a regulatory category it had never been in.
Which is not to say the safety concerns are invented
They are not, and the specific one is worth knowing about because almost nobody markets against it.
Exogenous ochronosis is a permanent blue-black or gray-brown discoloration that develops in skin treated with hydroquinone over long periods. It is the outcome the product was bought to prevent, arriving as a consequence of the product, and it does not reverse.
The foundational epidemiology comes from Hardwick and colleagues in South Africa, 1989, working with Black outpatients at two hospitals. In the general outpatient population, 15 percent of men and 42 percent of women had exogenous ochronosis. Among people specifically using skin lighteners, it rose to 69 percent.
And the detail that matters most: the authors found that even products limited to 2 percent hydroquinone or less, combined with a sunscreen, caused it.
Two percent is the cosmetic concentration. It is the strength that was sitting on American shelves without a prescription for decades and the strength most people assume is the safe one. The protective assumption — that ochronosis is a high-strength, prescription-grade, misuse problem — does not survive that paper. A 2026 review notes case reports of ochronosis after as little as three months of topical hydroquinone use.
Low-strength, over-the-counter hydroquinone is the safe version.
- Source
- Hardwick N, Van Gelder LW, Van der Merwe CA, Van der Merwe MP, "Exogenous ochronosis: an epidemiological study," British Journal of Dermatology 1989
- Participants
- Black outpatient populations at two South African hospitals
- Measured
- General outpatients and, separately, self-identified skin-lightener users
- Not measured
- Long-term prospective follow-up; a dose-duration threshold below which it does not occur
15% of men and 42% of women in the general outpatient group had exogenous ochronosis; 69% among lightener users. The authors found products at 2% or less, used with sunscreen, still caused it.
What is on the shelf now
The reclassification gets genuinely perverse on the shelf.
Hydroquinone at 4 percent, from a prescriber, is a supervised product with a clinician attached and a defined treatment course. That is the regulated path and it works.
Everything else went sideways rather than away. Products reformulated around ingredients that are not hydroquinone and are not regulated as drugs. Products continued to be sold through channels that do not answer to the FDA — imported, marketplace-shipped, sold from a shop counter in a box with a phone number on it. The FDA’s own post-2020 adverse event reports for skin-lightening products include rashes, facial swelling and ochronosis, which tells you the products did not stop existing.
So a shopper who used to buy a 2 percent cream at a pharmacy, with labeling and a manufacturer with a US address, now has a worse set of options than she had before: a prescription she may not be able to get an appointment for, or a jar from an unregulated channel where nobody has tested what is in it.
That last category is where the mercury is, and eight years of testing on it is its own piece.
Three jars, and which one is yours
If you are using hydroquinone for a diagnosed pigment problem, under supervision, on a defined course with an end date — that is the situation the evidence supports and I am not going to talk you out of it. It works. It is the benchmark other tyrosinase inhibitors get measured against for a reason.
If you have had the same jar going for a year and a half, topping it up, using it as maintenance, with no end date and no one checking — stop and look at the skin in daylight, not bathroom light. Ochronosis in its early stages looks like the hyperpigmentation getting worse, which is exactly the reading that makes somebody apply more.
And if a product promises lightening, has no clinician attached, and came from a channel where you could not name the manufacturer if asked — the question is not whether it contains hydroquinone. Hydroquinone would be the reassuring answer.
Evidence check: Moderate
Evidence level: strong for the regulatory history; the ochronosis prevalence figures come from a single 1989 observational study in one population.
Sources reviewed September 13, 2026: CARES Act, 2020, effective 23 September 2020; FDA, “FDA works to protect consumers from potentially harmful OTC skin lightening products.” Hardwick N et al., British Journal of Dermatology 1989, exogenous ochronosis epidemiology. Jones et al., review of skin depigmentation practices and cutaneous malignancy, 2026.
This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.